Technology Transfer and Entrepreneurship (Discontinued)
Volume 7, 2 Issues, 2020 ISSN: 2213-8102 (Online) ISSN: 2213-8099 (Print)
This journal supports open access
Aims & Scope
"Technology Transfer and Entrepreneurship" (TTE) publishes definitive reviews/mini-reviews articles including case histories covering a broad range of topics that underlie the business of biomedical research, specifically translating basic scientific discoveries into commercial opportunities. This includes understanding of the technology transfer process and entrepreneurship in academia, the biotechnology and pharmaceutical industries; directed towards economic development, better healthcare, and long-term job creation.
The journal scope includes economic insights on how technology is transferred within the bioscience and healthcare industries, and the underlying entrepreneurship that embodies scientific and biomedical research.
Dennis M. Gross Pennsylvania Drug Discovery Institute Doylestown, PA (USA) Biography
Biography of Dennis M. Gross
Dr. Gross received a masters (M.S.) in Biology from the California State University and his doctorate (Ph.D.) in Cell Biology from the University of California, Los Angeles. He did his postdoctoral training at Tulane University School of Medicine. He has also done postgraduate programs at the Wharton School, Harvard/Tufts Law Schools and MIT. Dr. Gross is also faculty in the Jefferson College of Biomedical Sciences and the Sydney Kimmel Medical College of Thomas Jefferson University, Professor of Experimental Therapeutics and Medicinal Chemistry in the Blumberg Institute and Adjunct Professor of Basic Sciences at The Commonwealth Medical College. He has published more than 120 scientific publications. He currently is also the CEO of the Pennsylvania Drug Discovery Institute.
Chad E. Beyer Promentis Pharmaceuticals Milwaukee, WI (USA) Biography
Biography of Chad E. Beyer
Dr. Beyer is President & CEO of Promentis Pharmaceuticals, Inc. He has nearly 20 years of experience in the research, discovery and business development of medications aimed to treat CNS and neurological disorders. Previously, Dr. Beyer served as the Head of Neurochemistry at Wyeth Pharmaceuticals in Princeton, NJ. During his career at Wyeth, Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, 3 patents, and co-edited "Next Generation Antidepressants." Dr. Beyer is also an adjunct faculty member at Thomas Jefferson University in Philadelphia where he teaches "Bioventure Management", a class focused on the business of doing science.